Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective
The advent of anti-HER2 targeted therapies has dramatically improved the outcome of HER2-positive breast cancer; however, resistance to treatment in the metastatic setting remains a challenge, highlighting the need for novel therapies. The arrival of new treatment options and clinical trials examini...
| Glavni autori: | , , , , , |
|---|---|
| Format: | Članak |
| Jezik: | English |
| Izdano: |
MDPI AG
2022-04-01
|
| Serija: | Current Oncology |
| Teme: | |
| Online pristup: | https://www.mdpi.com/1718-7729/29/4/222 |